Magainin Pharmaceuticals announces new research program for anti-angiogenesis agent - Squalamine - at Georgetown Univ Med Ctr. PRNewswire. www.prnewswire.com (Accessed 22 January 2000).

Sills AK Jr, Williams JI, Tyler BM, et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 1998;58:2784-92. View abstract.

Kikuchi K, Bernard EM, Sadownik A, et al. Antimicrobial activities of squalamine mimics. Antimicrob Agents Chemother 1997;41:1433-8. View abstract.

Moore KS, Wehrli S, Roder H, et al. Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci U S A 1993;90:1354-8. View abstract.

Magainin Presents Neuroblastoma Data for Squalamine at AACR Meeting. Available at: www.prnewswire.com (Accessed 3 April 2000).

Bhargava P, Marshall JL, Dahut W, et al. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin Cancer Res. 2001;7(12):3912-9. View abstract.

Garcia CA, Quiroz-Mercado H, Uwaydat S, et al. A phase I/II trial of intravenous squalamine lactate for treatment of choroidal neovascularization in age related macular degeneration (ARMD). Invest. Ophthal. Visual Sci. 2004;45(13):2362.

Rose V, Schiller J, Wood A, et al. Randomized phase II trial of weekly squalamine, carboplatin, and paclitaxel as first line therapy for advanced non-small cell lung cancer. J. Clin. Oncol. 2004;22(14 suppl):7109.

Wroblewski JJ, Hu AY. Topical squalamine 0.2% and intravitreal ranibizumab 0.5 mg as combination therapy for macular edema due to branch and central retinal vein occlusion: An open-label, randomized study. Ophthalmic Surg Lasers Imaging Retina. 2016;47(10):914-923. View abstract.

Herbst RS, Hammond LA, Carbone DP, et al. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2003;9(11):4108-15. View abstract.